Novartis plans to close Horsham R&D site in UK
With this move, Novartis has joined Pfizer, GlaxoSmithKline and AstraZeneca, who have recently closed their R&D units in the UK. The Horsham site has almost 950 full-time equivalent
Mediar Therapeutics has announced a collaboration and option agreement with Ono Pharmaceutical to develop new treatments for fibro-inflammatory diseases.